Merck Commits $1 Billion to Google Cloud AI for Drug Development, Halving Dossier Costs
Merck will invest up to $1 billion with Google Cloud over several years to fund AI infrastructure, engineers and Gemini Enterprise licensing. The collaboration will deploy AI across drug research, regulatory, manufacturing and commercial operations, halving dossier preparation time and cost globally.
1. Partnership Overview
Merck & Co has agreed to invest up to $1 billion in Google Cloud over multiple years to build AI infrastructure, hire engineers and license the Gemini Enterprise platform. The collaboration is structured as a long-term engagement, expected to span at least a decade.
2. AI Deployment Across Operations
Under the partnership, AI tools will be integrated throughout Merck’s drug development lifecycle, including running computerized simulation experiments, expediting regulatory document preparation and optimizing manufacturing and commercial processes.
3. Early Results and Scaling
Merck reports that initial use of Google Cloud’s AI technology has cut dossier compilation time and cost by half. The company plans to scale this capability in all major markets, moving beyond pilot projects to full global deployment.
4. Strategic Implications for Google Cloud
This deal strengthens Google Cloud’s footprint in life sciences and demonstrates its AI platform’s capabilities. The partnership could drive sustained revenue growth for Alphabet’s cloud division as AI adoption accelerates in the pharmaceutical sector.